Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
5 papers
Recent·Most cited
H. M. Parrington, N. Kose, E. Armstrong, L. S. Handal, S. Diaz, J. X. Reidy, J. Dong, G. B. E. Stewart-Jones, P. Shrivastava-Ranjan, S. Jain, C. G. Albarino, R. H. Carnahan, J. E. Crowe
The paper identifies potent human monoclonal antibodies against Sosuga virus, revealing epitope diversity and neutralization mechanisms.
bioRxiv · Nov 17, 2022Immunology
T. B. Engdahl, E. Binshtein, R. L. Brocato, N. A. A. Kuzmina, L. M. Principe, S. A. Kwilas, R. K. Kim, N. S. Chapman, M. S. Porter, P. Guardado-Calvo, F. A. Rey, L. S. Handal, S. M. Diaz, I. A. Zagol-Ikapitte, J. X. Reidy, , J. E. Crowe
This study maps antigenic sites and characterizes neutralizing antibodies against hantaviruses, identifying mechanisms and cross-protective potential for vaccine development.
bioRxiv · Jul 19, 2022Immunology
E. C. Chen, P. Gilchuk, S. J. Zost, P. A. Ilinykh, E. Binshtein, K. Huang, L. Myers, S. Bonissone, S. Day, C. R. Kona, A. Trivette, J. X. Reidy, R. E. Sutton, C. Gainza, S. Monroig, , J. E. Crowe
The paper analyzes the human antibody response to ebolavirus glycoprotein, identifying public clonotypes with neutralizing activity and implications for vaccine design.
bioRxiv · Jan 12, 2022 · PreprintImmunology
S. J. Zost, P. Gilchuk, J. B. Case, E. Binshtein, R. E. Chen, J. X. Reidy, A. Trivette, R. S. Nargi, R. E. Sutton, N. Suryadevara, L. E. Williamson, E. C. Chen, T. Jones, S. Day, L. Myers, , J. E. Crowe
The paper identifies potent neutralizing antibodies against SARS-CoV-2 that block receptor binding and protect animals, providing insights for vaccine and therapy development.
bioRxiv · May 22, 2020Immunology
S. J. Zost, P. Gilchuk, R. Chen, J. B. Case, J. X. Reidy, A. Trivette, R. S. Nargi, R. E. Sutton, N. Suryadevara, E. C. Chen, E. Binshtein, S. Shrihari, M. A. Ostrowski, H. Y. Chu, J. E. Didier, , J. E. Crowe
This study isolates and profiles human monoclonal antibodies against SARS-CoV-2 spike protein, identifying neutralizing antibodies targeting the receptor-binding domain.
bioRxiv · May 12, 2020Immunology